Nurofen Plus tablets containing rogue blister strips in additional 2 cartons

(Reckitt Benckiser (UK) Ltd) Recall of all unexpired stock of Nurofen Plus tablets in any pack size – class 1 action now. (EL(11)A/21)

25 August 2011

Class 1 drug alert

For immediate action

Class 1 patient-level recall

MDR 21-08/11

Product details

Reckitt Benckiser (UK) Ltd

Nurofen Plus Tablets containing rogue Seroquel XL 50mg tablets and Neurontin 100mg capsules

PL 00327/0082 and PL 00063/0376

Alert details

Pack size Batch number Expiry date PL First distributed
32 Tablets 13JJ 03/2014 00327/0082 30 April 2011
32 Tablets 57JJ 05/2014 00063/0376 21 June 2011
32 Tablets 49JJ 05/2014 00063/0376  1 July 2011

Following the recent issue of a Class 4 Drug Alert EL(11)A/21, Reckitt Benckiser (UK) Ltd has received further reports of rogue blister strips in cartons of two additional batches of Nurofen Plus tablets. One of the new batches contained Seroquel XL 50 mg tablets and one contained the Pfizer product Neurontin 100mg capsules.

Following discussions with the MHRA’s Defective Medicines Report Centre (DMRC), Reckitt Benckiser (UK) Ltd has decided to recall all remaining unexpired stock of Nurofen Plus tablets in any pack size.

Recipients are requested to contact patients wherever possible and ask them to return any Nurofen Plus tablets to the pharmacy where they were purchased or dispensed.

Wholesalers are requested to return any remaining stock to their original supplier for credit.

For medical information enquiries related to Seroquel XL Tablets please contact AstraZeneca Ltd medical information department on 0800 783 0033.

For medical information enquiries related to Neurontin 100mg capsules please contact Pfizer medical information department on 01304 616161.

For medical information enquiries related to Nurofen Plus Tablets please contact Reckitt Benckiser (UK) Ltd medical information department on 0500 455 456.

Recipients of this Drug Alert are requested to bring it to the attention of relevant professionals by copy of this letter. Primary care trusts are asked to forward this information to general practitioners, community pharmacists and relevant clinics by copy of this letter.

MHRA distribution

Further recipients by cascade:

Regional contacts for NHS trusts and provider units
Chief pharmacists: England, Scotland, Wales, Northern Ireland
Prison Health Policy Unit (DH)
Chief pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special Hospitals
Healthcare Commission for distribution to Independent Health Care Establishments
Primary care trusts (England)

Download documents

Published 17 December 2014